Reutova M A, Siuniakov S A, Siuniakov T S, Dorofeeva O A, Mametova L É, Neznamov G G
Eksp Klin Farmakol. 2011;74(11):6-13.
Self-evaluation of the effect of single-dose (15 mg) ladasten administration versus placebo has been studied in patients with neurasthenia diagnosis. Relationships between self-evaluation parameters and personal features, psychopathological and psychophysiological parameters of patients, drug action characteristics, and course treatment effectiveness have been analyzed. Results suggest that the self-rated high tolerability of ladasten treatment is comparable with that of placebo. No relationships are found between the self-evaluated single-dose effects of ladasten and personal features of patients. Correlations of the self-estimations and some psychopathological and psychophysiological parameters before treatment, main drug effects, and overall course treatment effectiveness are revealed, whereas the self-evaluation of placebo effect was related to personal features.
已对诊断为神经衰弱的患者进行了单剂量(15毫克)拉达司琼给药与安慰剂效果的自我评估研究。分析了自我评估参数与患者个人特征、心理病理和心理生理参数、药物作用特征以及疗程治疗效果之间的关系。结果表明,拉达司琼治疗的自我评定高耐受性与安慰剂相当。未发现拉达司琼单剂量效果的自我评估与患者个人特征之间存在关联。揭示了治疗前自我评估与一些心理病理和心理生理参数、主要药物效果以及总体疗程治疗效果之间的相关性,而安慰剂效果的自我评估与个人特征有关。